**Table 3: Odds ratios for the association between dose of last statin prescription and zoster, stratified by time since last exposure**

|  |  |
| --- | --- |
|  | Odds ratio (95% CI) |
| **Statin Use** | Model 1 | Model 2 | Model 3 |
| Never  | 1.00 | 1.00 | 1.00 |
|  Current |  |  |  |
|  Low | 1.20 (1.18, 1.23) | 1.17 (1.14, 1.19) | 1.14 (1.11, 1.16) |
|  Medium | 1.23 (1.19, 1.27) | 1.20 (1.16, 1.24) | 1.16 (1.12, 1.20) |
|  High | 1.40 (1.27, 1.54) | 1.35 (1.22, 1.50) | 1.27 (1.15, 1.41) |
|  <12m since stopping statins |  |  |  |
|  Low | 1.14 (1.09, 1.20) | 1.12 (1.07, 1.18) | 1.08 (1.03, 1.14) |
|  Medium | 1.18 (1.06, 1.31) | 1.12 (1.00, 1.25) | 1.07 (0.96, 1.20) |
|  High | 1.49 (1.03, 2.16) | 1.40 (0.94, 2.07) | 1.35 (0.91, 2.01) |
|  >12m since stopping statins |  |  |  |
|  Low | 1.15 (1.10, 1.21) | 1.13 (1.07, 1.18) | 1.09 (1.04, 1.15) |
|  Medium | 1.14 (1.00, 1.29)  | 1.12 (0.98, 1.28) | 1.08 (0.95, 1.24) |
|  High | 0.93 (0.47, 1.85) | 0.70 (0.33, 1.51) | 0.66 (0.30, 1.44) |
| Model 1 - Unadjusted modelModel 2 - Unadjusted model, restricted to patients that had no missing data in all descriptive variablesModel 3 - Adjusted for BMI category, smoking status, alcohol use, HIV, CVD, lymphoma, leukaemia, myeloma, haematopoietic stem cell transplantation, other immunosuppressive therapy, other unspecified cellular immune deficiencies, oral corticosteroids, rheumatoid arthritis, systemic lupus erythematosus, COPD, asthma, CKD, depression, cancer, and diabetes |